The long-term outcomes of systemic vasculitis.

  title={The long-term outcomes of systemic vasculitis.},
  author={Kerstin Westman and Oliver Flossmann and Gina Gregorini},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  volume={30 Suppl 1},
  • K. WestmanO. FlossmannG. Gregorini
  • Published 1 April 2015
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Patients with generalized ANCA-associated small vessel vasculitis (AAV) have a very poor outcome if the ANCA-associated vasculitis is not diagnosed, evaluated and treated properly. The introduction of treatment with immunosuppressive therapy has improved patient survival dramatically but with considerable side effects. Besides, almost 50% of surviving patients experience a relapse of vasculitis. Since 1995, the European Vasculitis Society (EUVAS) has designed and conducted several clinical… 

Tables from this paper

Clinical Trials in Vasculitis

The treatment options of AAV, which includes an induction and a maintenance phase, is dependent on the severity of the disease and a number of questions remain unanswered with regard to the optimal treatment strategy.

ANCA-associated vasculitis with dominant renal involvement: clinical and morphological presentation and outcomes

An unfavorable renal prognosis for ANCA-V determined by severe renal dysfunction due to inflammatory and fibrotic alterations of the organ can be significantly improved by adequate therapy with the achievement of higher patient's and kidney’s survival.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation

Current strategies include avoiding transplantation within one year of complete clinical remission and thoroughly assessing the recipient for early signs of renal or systemic vasculitis, particularly focusing on de novo pauci-immune glomerulonephritis.

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series

This study shows a partial efficacy of rituximab in renal function recovery and a low risk of infectious complications in patients with MPO vasculitis with severe renal involvement, in particular in the short term.

ANCA-associated vasculitis with renal involvement

This review will focus on kidney involvement in AAV with an overview of the clinical–pathological characteristics and therapeutic strategy for these conditions.

Incidence and clinical predictors of infections in patients treated with severe systemic ANCA-associated vasculitis.

The findings indicate the need for high vigilance for infections and close follow-up of comorbidities when treating AAV, and those who suffer infection during induction immunosuppression have worse long-term survival.

Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn.

  • D. CornecE. Cornec-Le GallU. Specks
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2017
This review summarizes the evidence derived from clinical trials performed during the last 30 years and the remaining clinical unmet needs that new studies aim to address, and assesses different strategies to reduce cumulative glucocorticoid doses currently used for induction and maintenance of remission.

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis

It is suggested that the initial clinical presentation is an important predictor for survival in patients without gastrointestinal, cardiovascular or renal involvement at diagnosis.

Unmet Needs in the Pathogenesis and Treatment of Vasculitides

Rituximab or anti-TNF alfa may represent a possible alternative therapy in case of refractory or difficult to treat polyarteritis nodosa (PAN) patients and the role of tocilizumab or other biological agents without GCs needs to be investigated.

Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial

MTX may be effective and safe for remission-maintenance in AAV, and no significant differences in adverse event frequencies were observed.



Long‐term outcome of antineutrophil cytoplasmic antibody‐associated small vessel vasculitis after renal transplantation

It is concluded that patient and graft survival rates compare favorably with those in control group that the recurrence rate is very low and that there is no increase in the incidence of cancer or in CV mortality.

ANCA-associated vasculitis with renal involvement: an outcome analysis.

The data underscore the pathogenetic potential of ANCA by demonstrating a more aggressive disease state and a poorer outcome in patients with PR3-ANCA.

Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies.

Although mortality from ANCA-associated vasculitis has decreased, morbidity remains a common problem and high early-disease activity may identify patients at high risk of long-term organ damage, allowing more effective individualized therapy.

Relapses in patients with a systemic vasculitis.

The considerable accumulative non-fatal relapse rate contrasts with the very good long-term survival rates, and confirms the importance of long- term follow-up in systemic vasculitis.

Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis.

BACKGROUND Recurrent antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis (ANCA-SVV) after renal transplantation has been described in case series. However, general

Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study

Current treatment of severe AH leads to remission but long-term mortality remains high, and Concurrent renal failure and older age were associated with higher mortality.

Long-Term Outcome of Patients with Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis with Renal Involvement

Background: Despite treatment, renal involvement in antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis is still associated with significant long-term mortality and remains an

ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.

Older patients have a poorer prognosis due to more severe renal involvement and increased sensitivity to adverse effects of treatment, and the importance of careful dosing of cyclophosphamide: in those aged over 65 yr a 25% dose reduction is safe and reduces the risk of leucopenia.

Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study.

  • A. BoothM. Almond D. Jayne
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2003

Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis.

AAV patients with renal involvement who needed RRT had the worst survival probability and the only major determinants for long-term renal survival were renal function at 6 months and renal relapses.